Brief: Avidity Biosciences' Del-zota Shows Disease Reversal in Key Endpoints
10/09/2025 12:48
Sept 10 (Reuters) - Avidity Biosciences Inc RNA.O: AVIDITY BIOSCIENCES' DEL-ZOTA DEMONSTRATED REVERSAL OF DISEASE PROGRESSION ACROSS KEY FUNCTIONAL ENDPOINTS IN EXPLORE44® AND EXPLORE44-OLE™ PHASE 1/2 TRIAL IN PEOPLE LIVING WITH DMD44 Source text: ID:nPn1Xx2nBa Further company coverage: RNA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avidity Biosciences
See all newsFactbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Brief: Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off